SCHEMBL26457526

SCHEMBL26457526

CCc1ccc2c(n1)NCCO2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
HSD17B10 Q99714 1/20 0.40
GRM5 P41594 2/20 0.39
ITGB3 P05106 4/20 0.36
ITGAV P06756 4/20 0.36
ITGB1 P05556 1/20 0.36
ITGA5 P08648 1/20 0.36
PDE10A Q9Y233 1/20 0.34
ADRA2A P08913 3/20 0.34
ADRA2C P18825 3/20 0.34
ADRA1D P25100 3/20 0.34
ADRA1A P35348 3/20 0.34
ADRA1B P35368 3/20 0.34
ADRA2B P18089 2/20 0.34
FABP6 P51161 1/20 0.33
ALOX5AP P20292 3/20 0.32
FEN1 P39748 3/20 0.32
EED O75530 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26538782 0.87 ITGB3 (0.39) ALDH1A1GAAMAPTHSD17B10GRM5
SCHEMBL8172614 0.84 ITGAV (0.38) ALDH1A1GAAMAPTHSD17B10GRM5
SCHEMBL14476045 0.83 GRM5 (0.39) ALDH1A1GAAMAPTHSD17B10GRM5
SCHEMBL12807108 0.83 KCNH2 (0.42) ALDH1A1GAAMAPTHSD17B10GRM5
SCHEMBL24440037 0.81 ITGAV (0.39) ALDH1A1GAAMAPTHSD17B10GRM5
SCHEMBL2494472 0.81 ITGAV (0.41) ALDH1A1GAAMAPTHSD17B10GRM5
SCHEMBL8039387 0.78 ITGAV (0.40) ALDH1A1GAAMAPTHSD17B10GRM5
SCHEMBL2492111 0.77 GAA (0.47) ALDH1A1GAAMAPTHSD17B10GRM5
SCHEMBL24630899 0.77 ITGB3 (0.38) ALDH1A1GAAMAPTHSD17B10GRM5
SCHEMBL8325969 0.75 ITGAV (0.40) GRM5ITGB3ITGAVITGB1ITGA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230136194-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230136194-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF ABCG2, CYP4F8, CYP3A5 ALDH1A1 440/4885GAA 1788/4885MAPT 3705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.